The HALT-IT trial is assessing whether early administration of tranexamic acid in people with acute gastrointestinal bleeding can reduce their risk of dying in the hospital. The trial is also measuring the effects of the treatment on re-bleeding, non-fatal vascular events, blood transfusion, surgical intervention and general health status. The HALT-IT trial began recruitment on 4 July 2013 and is aiming to recruit 8,000 patients from hospital worldwide by 30 November 2017.

Gastrointestinal bleeding is a common emergency with a 10-15% death rate. An effective treatment could save thousands of lives worldwide, In the CRASH-2 trial, we showed that, if given within 1 hour, tranexamic acid reduces mortality in bleeding trauma patients. Specifically, tranexamic acid reduces the risk of bleeding to death by about one third, with no increase in side effects. If tranexamic acid was shown to have similar effects in gastrointestinal bleeding, this would be a major advance.

7535 patients randomised 
(last updated 25/09/2017) 

  • Professor Muttiullah Khan, Head of Department at Unit II Holy Family Hospital Rawalpindi & National Coordinator in Pakistan had some fantastic comments to share with the HALT-IT team. Please read in full in our January Newsletter.

    Read Post
  • Our first Newsletter of 2017 - A huge thank to all for randomising over 6000 patients.

    Read Post
  • Read Post
  • Please check current newsletters for any updates, news and collaborators contributions.

    Read Post
  • September 2016 Newsletter is now available online. Celebrating having reached 5000 patients with our top recruiters as well as with our newly joined hospitals.

    Read Post
  • The Principal Investigator at Queen Elizabeth Hospital (QEH), Birmingham Dr Elaine Hardy has an excellent team working on the HALT-IT trial. She explains how the trial has been so successful at QEH.

    Read Post